ArticleBMC medicine2025
STI testing and diagnosis rates among patients with Mpox in 2 populous US cities, 2022.
Article in BMC medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundMpox is recognized as a sexually transmitted infection, and the 2022 epidemic and 2024 resurgence of mpox cases through sexual transmission highlighted the need for sexually transmitted infection (STI) testing. Our objective was to observe rates of STI testing and STI diagnoses in patients with confirmed mpox in Houston, Texas and New York City, New York (NY).
methodsThis was a retrospective cohort study involving manual review of confirmed mpox cases at three large clinical centers in Houston, Texas and New York City, NY. Descriptive statistics were calculated for rates of STI testing and new diagnoses of syphilis, chlamydia and gonorrhea.
resultsThere were 404 patients in the cohort from the three different clinical sites. The median age was 33 years. 66% underwent STI testing within two weeks of their mpox diagnosis. Among those who were tested, there were 71 patients with a new STI. Syphilis was the most newly diagnosed STI with 31 new cases. Most of the chlamydia and gonorrhea cases were extragenital (81%). Rates of chlamydia and gonorrhea tended to be higher in patients reporting site-specific symptoms (ex. pharyngitis, urethritis) than in asymptomatic patients. However, rates of STI testing were still low even in patients reporting site-specific symptoms. 63.6% of those reporting urinary symptoms, 51.9% of those reporting rectal symptoms and 47.4% reporting pharyngitis symptoms were tested for site-specific chlamydia and gonorrhea.
conclusionsOur findings highlight a gap in STI testing even in patients at high risk presenting with mpox, a sexually transmitted infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.